COGT

Cogent Biosciences (COGT)

Cogent Biosciences Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:COGT

1 2 3 4 5 6 7 8 9 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/06/14	20 : 30	GlobeNewswire Inc.	Cogent Biosciences Announces Additional Clinical Data from Part 1 of its Ongoing SUMMIT Trial Evaluating Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)	NASDAQ:COGT	Cogent Biosciences Inc
2024/06/14	08 : 18	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:COGT	Cogent Biosciences Inc
2024/06/14	08 : 14	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:COGT	Cogent Biosciences Inc
2024/06/14	08 : 11	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:COGT	Cogent Biosciences Inc
2024/06/14	08 : 07	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:COGT	Cogent Biosciences Inc
2024/06/13	19 : 06	Edgar (US Regulatory)	Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]	NASDAQ:COGT	Cogent Biosciences Inc
2024/06/13	10 : 01	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:COGT	Cogent Biosciences Inc
2024/06/06	05 : 02	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:COGT	Cogent Biosciences Inc
2024/05/30	05 : 03	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:COGT	Cogent Biosciences Inc
2024/05/30	05 : 01	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:COGT	Cogent Biosciences Inc
2024/05/24	06 : 05	GlobeNewswire Inc.	Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer	NASDAQ:COGT	Cogent Biosciences Inc
2024/05/24	06 : 01	GlobeNewswire Inc.	Cogent Biosciences Announces Positive Updated Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST) at ASCO Annual Meeting	NASDAQ:COGT	Cogent Biosciences Inc
2024/05/07	21 : 26	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:COGT	Cogent Biosciences Inc
2024/05/07	21 : 19	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:COGT	Cogent Biosciences Inc
2024/05/07	21 : 00	GlobeNewswire Inc.	Cogent Biosciences Reports First Quarter 2024 Financial Results	NASDAQ:COGT	Cogent Biosciences Inc
2024/04/09	22 : 00	GlobeNewswire Inc.	Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor	NASDAQ:COGT	Cogent Biosciences Inc
2024/02/27	06 : 34	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:COGT	Cogent Biosciences Inc
2024/02/26	23 : 13	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:COGT	Cogent Biosciences Inc
2024/02/26	22 : 30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:COGT	Cogent Biosciences Inc
2024/02/26	22 : 00	GlobeNewswire Inc.	Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results	NASDAQ:COGT	Cogent Biosciences Inc
2024/02/23	04 : 30	GlobeNewswire Inc.	Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis	NASDAQ:COGT	Cogent Biosciences Inc
2024/02/17	08 : 55	Edgar (US Regulatory)	Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]	NASDAQ:COGT	Cogent Biosciences Inc
2024/02/17	08 : 43	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:COGT	Cogent Biosciences Inc
2024/02/15	06 : 05	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:COGT	Cogent Biosciences Inc
2024/02/15	02 : 51	Edgar (US Regulatory)	Form SC 13G - Statement of acquisition of beneficial ownership by individuals	NASDAQ:COGT	Cogent Biosciences Inc
2024/02/14	22 : 35	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:COGT	Cogent Biosciences Inc
2024/02/14	21 : 00	GlobeNewswire Inc.	Cogent Biosciences Announces Oversubscribed $225 Million Private Placement	NASDAQ:COGT	Cogent Biosciences Inc
2024/02/10	06 : 22	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:COGT	Cogent Biosciences Inc
2024/02/05	23 : 00	GlobeNewswire Inc.	Cogent Biosciences to Present SUMMIT Part 1b Data with Bezuclastinib in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2024 AAAAI Annual Meeting	NASDAQ:COGT	Cogent Biosciences Inc
2024/01/26	06 : 36	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:COGT	Cogent Biosciences Inc